Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)

NCT03333928 is registered in ClinicalTrials.gov with HighTide Therapeutics (Hong Kong) Limited as lead sponsor.

NCT NCT03333928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03333928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Phase
Phase 2
Overall status
Completed
Start date
February 9, 2018
Completion date
August 14, 2020
Enrollment
59 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis (psc)